Yukio Tani - Ono Pharmaceutical Executive Officer, Director of Public Relations
| OPHLY Stock | USD 3.67 0.07 1.87% |
Director
Yukio Tani is Executive Officer, Director of Public Relations of Ono Pharmaceutical Co since 2018.
| Tenure | 6 years |
| Phone | 81 6 6263 5670 |
| Web | https://www.ono-pharma.com |
Ono Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.1204 % which means that it generated a profit of $0.1204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1605 %, meaning that it generated $0.1605 on every $100 dollars invested by stockholders. Ono Pharmaceutical's management efficiency ratios could be used to measure how well Ono Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Peter Wendell | Merck Company | 70 | |
| Vctor Deu | Grifols SA ADR | 47 | |
| Jennifer Doudna | Johnson Johnson | 57 | |
| Kathy Warden | Merck Company | 49 | |
| Dan Littman | Pfizer Inc | 68 | |
| Robert Bertolini | Bristol Myers Squibb | 58 | |
| Iain Mackay | GSK plc | 61 | |
| Frederick Waddell | AbbVie Inc | 67 | |
| Meghan Rivera | Organon Co | N/A | |
| Jesse Goodman | GlaxoSmithKline PLC ADR | 69 | |
| Ronald Williams | Johnson Johnson | 71 | |
| Mark Weinberger | Johnson Johnson | 59 | |
| Satoshi Suzuki | Santen Pharmaceutical Co | N/A | |
| Julie ACA | GlaxoSmithKline PLC ADR | 62 | |
| Mary Beckerle | Johnson Johnson | 66 | |
| Phyllis Yale | Bristol Myers Squibb | 63 | |
| Michel Demare | AstraZeneca PLC ADR | 62 | |
| Genevieve Berger | AstraZeneca PLC ADR | 64 | |
| Ann Fudge | Novartis AG ADR | 70 | |
| Anne Mulcahy | Johnson Johnson | 68 | |
| Vivienne Cox | GlaxoSmithKline PLC ADR | 61 | |
Management Performance
| Return On Equity | 0.16 | |||
| Return On Asset | 0.12 |
Ono Pharmaceutical Leadership Team
Elected by the shareholders, the Ono Pharmaceutical's board of directors comprises two types of representatives: Ono Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ono. The board's role is to monitor Ono Pharmaceutical's management team and ensure that shareholders' interests are well served. Ono Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ono Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gyo Sagara, CEO and President and Representative Director | ||
| Hiromu Habashita, Executive Officer, Chief Director of Research | ||
| Katsuji Teranishi, Head of Marketing Strategy Planning, Deputy Director of Sales and Marketingl and Corporate Officer | ||
| Toshihiro Tsujinaka, Executive Officer, Senior Director of Oncology in Main Sales Unit | ||
| Shozo Matsuoka, Executive Officer, Manager of R & D Strategy Office | ||
| Kiyoaki Idemitsu, Exec Officer | ||
| Hiroshi Ichikawa, Sr. Director of Metropolitan Area Management and Metropolitan Area First Branch and Corporate Officer | ||
| Isao Ono, Executive Officer, Manager of Environmental Management Office, Director | ||
| Yukio Tani, Executive Officer, Director of Public Relations | ||
| Toichi Takino, Executive Director of Corporate Devel. and Strategy and Corporate Officer |
Ono Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ono Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.35 % | |||
| Current Valuation | 11.13 B | |||
| Shares Outstanding | 1.47 B | |||
| Shares Owned By Institutions | 0.03 % | |||
| Price To Earning | 18.66 X | |||
| Price To Book | 2.34 X | |||
| Price To Sales | 0.03 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Ono Pink Sheet Analysis
When running Ono Pharmaceutical's price analysis, check to measure Ono Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ono Pharmaceutical is operating at the current time. Most of Ono Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Ono Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ono Pharmaceutical's price. Additionally, you may evaluate how the addition of Ono Pharmaceutical to your portfolios can decrease your overall portfolio volatility.